Sarepta Therapeutics to Announce Second Quarter 2020 Financial Results and Recent Corporate Developments on August 5, 2020
July 29, 2020 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., July 29, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2020 financial...
Sarepta Therapeutics Receives Fast Track Designation for SRP-9001 Micro-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
July 24, 2020 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., July 24, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug...
Sarepta Therapeutics Launches “Rare Lessons” Program to Promote Greater Diversity and Inclusion in the Classroom and Support Awareness of Rare Diseases
July 15, 2020 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., July 15, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the launch of Rare Lessons,...
Sarepta Therapeutics Signs Agreement with Hansa Biopharma for Imlifidase
July 02, 2020 07:00 ET
|
Sarepta Therapeutics, Inc.
-- Exclusive worldwide license enables Sarepta to develop and promote imlifidase as a pre-treatment for gene therapy in Duchenne and Limb-girdle muscular dystrophy patients who have pre-existing...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 30, 2020 18:15 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2020 that...
Sarepta Therapeutics Announces Retirement of Sandy Mahatme, Chief Financial Officer and Chief Business Officer
June 30, 2020 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the retirement of Sandy...
Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Casimersen (SRP-4045) for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45
June 26, 2020 08:30 ET
|
Sarepta Therapeutics, Inc.
-- Casimersen is designed for the treatment of exon 45 amenable patients, approximately eight percent of patients with Duchenne -- -- Casimersen is the third exon-skipping medicine using the...
Sarepta Therapeutics and Codiak BioSciences Collaborate to Research and Develop Exosome-Based Therapeutics for Rare Diseases
June 22, 2020 08:00 ET
|
Sarepta Therapeutics, Inc.
- Alliance to explore the utility of engineered exosomes developed with Codiak’s engEx™ Platform to deliver gene therapy, gene editing and RNA technologies - - Two-year, global research and option...
Sarepta Therapeutics and Selecta Biosciences Enter into Research License and Option Agreement for Selecta’s ImmTOR Immune Tolerance Platform in Neuromuscular Diseases
June 18, 2020 08:30 ET
|
Sarepta Therapeutics, Inc.
– Application of ImmTOR plus Sarepta’s investigational gene therapies will be evaluated for Duchenne Muscular Dystrophy and Limb-Girdle Muscular Dystrophies – CAMBRIDGE, Mass. and WATERTOWN, Mass.,...
Sarepta Therapeutics Announces Positive Safety and Efficacy Data from the SRP-9001 Micro-Dystrophin Gene Therapy Trial Published in JAMA Neurology
June 15, 2020 11:00 ET
|
Sarepta Therapeutics, Inc.
-- Results at one year demonstrate continued safety and tolerability of SRP-9001 micro-dystrophin gene therapy in four patients with Duchenne muscular dystrophy -- -- Confirmed vector transduction...